Abstract
The objective of gene therapy is to manipulate/modify the gene expression or modify living cell characteristics for therapeutic utilization. It aims to achieve therapeutic effects by either inserting novel genes, rectifying or substituting the genes that are abnormal, or modifying the pre-existing gene expression. The therapy shows potential in addressing a diverse array of genetic and acquired disorders. This includes certain types of cancer, hereditary genetic diseases like muscular dystrophy and cystic fibrosis, and other circumstances where genetic factors have a significant influence. Gene therapy can be accomplished by several mechanisms, namely, gene editing, gene replacement, gene addition, and gene silencing. Gene replacement involves the replacement of malfunctioning genes with the functional copy in the patient’s cells. Gene editing pertains to technologies like CRISPR-Cas9 to edit the specific gene in the patient’s cells. In a genetic condition caused by a missing gene, the gene addition procedure can add a functioning copy of that gene to the patient’s cells to compensate for the deficiencies. In genetic disorders resulting from the overexpression of genes, gene silencing can be applied to reduce the expression or downregulation of these genes by techniques such as RNA interference (RNAi). Gene therapy holds promising possibilities and represents an innovative approach to drug delivery. It has the capacity to eliminate the necessity for frequent injections of proteins or medications, thereby alleviating the challenges associated with adhering to external drug schedules.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aigner A (2007) Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76:9–21
Arabi F, Mansouri V, Ahmadbeigi N (2022) Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother 153:113324
Bobbin ML, Rossi JJ (2016) RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol 56:103–122
Bulcha JT, Wang Y, Ma H, Tai PW, Gao G (2021) Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther 6(1):53
Chen J, Guo Z, Tian H, Chen X (2016) Production and clinical development of nanoparticles for gene delivery. Mol Ther Methods Clin Dev 3:16023
Chen W, Hu Y, Ju D (2020) Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B 10(8):1347–1359
Cockrell AS, Kafri T (2007) Gene delivery by lentivirus vectors. Mol Biotechnol 36:184–204
Cotrim AP, Baum BJ (2008) Gene therapy: some history, applications, problems, and prospects. Toxicol Pathol 36(1):97–103
Das SK, Menezes ME, Bhatia S, Wang XY, Emdad L, Sarkar D, Fisher PB (2015) Gene therapies for cancer: strategies, challenges and successes. J Cell Physiol 230(2):259–271
Ghosh S, Brown AM, Jenkins C, Campbell K (2020) Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges. Applied Biosafety 25(1):7–18
Guo X, Huang L (2012) Recent advances in nonviral vectors for gene delivery. Acc Chem Res 45(7):971–979
Lundstrom K (2018) Viral vectors in gene therapy. Diseases 6(2):42
Lundstrom K (2019) RNA viruses as tools in gene therapy and vaccine development. Genes 10(3):189
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M (2021) Current clinical applications of in vivo gene therapy with AAVs. Mol Ther 29(2):464–488
Ng AP, Alexander WS (2017) Haematopoietic stem cells: past, present and future. Cell death discovery 3(1):1–4
Pola S, Padi D (2023) “Gene therapy”: ethical and regulatory issues. In: Novel platforms for drug delivery applications. Woodhead Publishing, Cambridge, pp 607–618
Schlimgen R, Howard J, Wooley D, Thompson M, Baden LR, Yang OO, Christiani DC, Mostoslavsky G, Diamond DV, Duane EG, Byers K (2016) Risks associated with lentiviral vector exposures and prevention strategies. J Occup Environ Med 58(12):1159
Verma IM, Weitzman MD (2005) Gene therapy: twenty-first century medicine. Annu Rev Biochem 74:711–738
Wang H, La Russa M, Qi LS (2016) CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 85:227–264
Wang D, Tai PW, Gao G (2019) Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 18(5):358–378
Wirth T, Parker N, Ylä-Herttuala S (2013) History of gene therapy. Gene 525(2):162–169
Xu W, Jiang X, Huang L (2019) RNA interference technology. Compr Biotechnol 2019:560
Zhang F, Wen Y, Guo X (2014) CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet 23(R1):R40–R46
Zheng CX, Wang SM, Bai YH, Luo TT, Wang JQ, Dai CQ, Guo BL, Luo SC, Wang DH, Yang YL, Wang YY (2018) Lentiviral vectors and adeno-associated virus vectors: useful tools for gene transfer in pain research. Anat Rec 301(5):825–836
Zu H, Gao D (2021) Non-viral vectors in gene therapy: recent development, challenges, and prospects. AAPS J 23(4):78
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Narayanan, D.K.L. (2024). Gene Therapy in Molecular Biology and Drug Delivery. In: Bose, S., Shukla, A.C., Baig, M.R., Banerjee, S. (eds) Concepts in Pharmaceutical Biotechnology and Drug Development . Interdisciplinary Biotechnological Advances. Springer, Singapore. https://doi.org/10.1007/978-981-97-1148-2_14
Download citation
DOI: https://doi.org/10.1007/978-981-97-1148-2_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-97-1147-5
Online ISBN: 978-981-97-1148-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)